TOI Stock Analysis: Oncology Institute | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 528m USD | 12M Return: 105.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.37M
Qual. Beats: 1
Rev. Trend: 99.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Oncology Institute, Inc. (NASDAQ: TOI) is a US-based oncology care provider founded in 2007 and headquartered in Cerritos, California. The company operates through three segments-Specialty Pharmacy, Patient Services, and Clinical Trials & Other-delivering physician services, in-house infusion, radiation therapy, specialty pharmacy dispensing (both in-office and mail-order), outpatient blood product transfusions, clinical trial management, and palliative care programs. It also offers patient support services such as educational seminars, support groups, counseling, and 24/7 assistance, and runs combined community clinics with infusion suites. The company primarily serves adult and senior cancer patients.
TOI went public in November 2021 and is classified as a small-cap stock within the Health Care sector. Its integrated, value-based model combines clinical care with in-house pharmacy dispensing, a structure that aims to streamline treatment delivery in the outpatient setting. Demand for community-based oncology services has been supported by long-term trends including an aging US population and a broader shift of cancer care away from hospital inpatient settings toward outpatient clinics.
- Specialty pharmacy revenue expansion drives higher contribution margins
- Medicare reimbursement rate changes pressure patient services profitability
- Clinical trials revenue grows on increased pharma sponsor activity
| Net Income: -43.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA -3.62 > 1.0 |
| NWC/Revenue: 6.87% < 20% (prev 11.73%; Δ -4.85% < -1%) |
| CFO/TA -0.13 > 3% & CFO -21.8m > Net Income -43.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.02b) vs 12m ago 1.22k% < -2% |
| Gross Margin: 14.82% > 18% (prev 14.70%; Δ 0.12% > 0.5%) |
| Asset Turnover: 328.5% > 50% (prev 245.8%; Δ 82.72% > 0%) |
| Interest Coverage Ratio: -4.71 > 6 (EBIT TTM -36.0m / Interest Expense TTM 7.64m) |
| A: 0.22 (Total Current Assets 116.9m - Total Current Liabilities 79.4m) / Total Assets 168.2m |
| B: -1.63 (Retained Earnings -273.9m / Total Assets 168.2m) |
| C: -0.22 (EBIT TTM -36.0m / Avg Total Assets 166.1m) |
| D: -0.09 (Book Value of Equity -16.3m / Total Liabilities 184.5m) |
| Altman-Z'' = -5.39 = D |
| DSRI: 0.88 (Receivables 59.5m/49.7m, Revenue 545.8m/403.2m) |
| GMI: 0.99 (GM 14.70% / 14.82%) |
| AQI: 0.81 (AQ_t 0.11 / AQ_t-1 0.13) |
| SGI: 1.35 (Revenue 545.8m / 403.2m) |
| TATA: -0.13 (NI -43.5m - CFO -21.8m) / TA 168.2m) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 5.89 with a total of 3,928,104 shares traded. Over the past week, the price has changed by +11.55%, over one month by +25.85%, over three months by +91.23% and over the past year by +105.23%.
Current recommended Stop Loss: 5.20 (which is 11.7% or 1.9 ATR below the current price).
Oncology Institute has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy TOI.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 7.8 | 31.6% |
P/S = 0.9673
P/B = 0.7617
Revenue TTM = 545.8m USD
EBIT TTM = -36.0m USD
EBITDA TTM = -29.2m USD
Long Term Debt = 78.6m USD (from longTermDebt, last quarter)
Short Term Debt = 7.40m USD (from shortTermDebt, last quarter)
Debt = 131.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 26.2m
Net Debt = 100.8m USD (calculated: Debt 131.1m - CCE 30.3m)
Enterprise Value = 628.7m USD (527.9m + Debt 131.1m - CCE 30.3m)
Interest Coverage Ratio = -4.71 (Ebit TTM -36.0m / Interest Expense TTM 7.64m)
EV/FCF = -24.44x (Enterprise Value 628.7m / FCF TTM -25.7m)
FCF Yield = -4.09% (FCF TTM -25.7m / Enterprise Value 628.7m)
FCF Margin = -4.71% (FCF TTM -25.7m / Revenue TTM 545.8m)
Net Margin = -7.97% (Net Income TTM -43.5m / Revenue TTM 545.8m)
Gross Margin = 14.82% ((Revenue TTM 545.8m - Cost of Revenue TTM 464.9m) / Revenue TTM)
Gross Margin QoQ = 14.72% (prev 16.04%)
Tobins Q-Ratio = 3.74 (Enterprise Value 628.7m / Total Assets 168.2m)
Interest Expense / Debt = 5.83% (Interest Expense 7.64m / Debt 131.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -28.4m (EBIT -36.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.47 (Total Current Assets 116.9m / Total Current Liabilities 79.4m)
Debt / Equity = -8.05 (negative equity) (Debt 131.1m / totalStockholderEquity, last quarter -16.3m)
Debt / EBITDA = -3.45 (negative EBITDA) (Net Debt 100.8m / EBITDA -29.2m)
Debt / FCF = -3.92 (negative FCF - burning cash) (Net Debt 100.8m / FCF TTM -25.7m)
Total Stockholder Equity = -13.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.19% (Net Income -43.5m / Total Assets 168.2m)
RoE = 326.8% (negative equity) (Net Income TTM -43.5m / Total Stockholder Equity -13.3m)
RoCE = -55.14% (EBIT -36.0m / Capital Employed (Equity -13.3m + L.T.Debt 78.6m))
RoIC = -41.23% (negative operating profit) (NOPAT -28.4m / Invested Capital 69.0m)
WACC = 7.68% (E(527.9m)/V(659.0m) * Re(8.44%) + D(131.1m)/V(659.0m) * Rd(5.83%) * (1-Tc(0.21)))
Discount Rate = 8.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 221.7%
[DCF] Fair Price = unknown (Cash Flow -25.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.53 | # QB: 1
Revenue Correlation: 99.11 | Revenue CAGR: 23.52% | SUE: 0.04 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.07 | Chg30d=+0.00% | Revisions=+25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.04 | Chg30d=-12.50% | Revisions=+17% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.15 | Chg30d=-3.45% | Revisions=+57% | GrowthEPS=+72.2% | GrowthRev=+31.1%
EPS next Year (2027-12-31): EPS=-0.08 | Chg30d=+11.11% | Revisions=+25% | GrowthEPS=+46.7% | GrowthRev=+24.5%
[Analyst] Revisions Ratio: +58% (up=8, down=1)